Table 6 Simulation 1A subgroup discovery using gradient random forest (five subgroups found)
From: Preventing false discovery of heterogeneous treatment effect subgroups in randomized trials
Single agent | Combination | ASD | |
|---|---|---|---|
Group 1: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.05\left(-0.30,0.20\right) \) | |||
n = 35 | n = 38 | ||
Age (years) | 64.6 (±5.6) | 65.0 (±5.1) | 0.08 |
Stage 4 | |||
No | 1 (2.9%) | 0 (0.0%) | 0.24 |
Yes | 34 (97.1%) | 38 (100.0%) | 0.24 |
Site | |||
Visceral | 19 (54.3%) | 15 (39.5%) | 0.3 |
Bone only | 5 (14.3%) | 6 (15.8%) | 0.04 |
Other | 11 (31.4%) | 17 (44.7%) | 0.28 |
Previous treatment | |||
None | 24 (68.6%) | 19 (50.0%) | 0.38 |
Chemo only | 6 (17.1%) | 8 (21.1%) | 0.1 |
Hormonal only | 3 (8.6%) | 4 (10.5%) | 0.07 |
Chemo + hormonal | 2 (5.7%) | 7 (18.4%) | 0.4 |
ECOG score | |||
0 | 15 (42.9%) | 14 (36.8%) | 0.12 |
1 | 20 (57.1%) | 24 (63.2%) | 0.12 |
Disease free >12 months adjuvant to recurrence | |||
Yes | 35 (100.0%) | 38 (100.0%) | 0 |
Group 2: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.01\left(-0.42,0.39\right) \) | |||
n = 11 | n = 15 | ||
Age (years) | 63.9 (±4.9) | 64.2 (±4.1) | 0.06 |
Stage 4 | |||
Yes | 11 (100.0%) | 15 (100.0%) | 0 |
Site | |||
Other | 11 (100.0%) | 15 (100.0%) | 0 |
Previous treatment | |||
Chemo only | 2 (18.2%) | 5 (33.3%) | 0.35 |
Hormonal only | 5 (45.5%) | 9 (60.0%) | 0.29 |
Chemo + hormonal | 4 (36.4%) | 1 (6.7%) | 0.78 |
ECOG score | |||
0 | 3 (27.3%) | 8 (53.3%) | 0.55 |
1 | 8 (72.7%) | 7 (46.7%) | 0.55 |
Disease free >12 months adjuvant to recurrence | |||
No | 11 (100.0%) | 15 (100.0%) | 0 |
Group 3: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.33\left(-0.92,0.25\right) \) | |||
n = 12 | n = 6 | ||
Age (years) | 65.7 (±7.6) | 65.0 (±4.4) | 0.12 |
Stage 4 | |||
Yes | 12 (100.0%) | 6 (100.0%) | 0 |
Site | |||
Other | 12 (100.0%) | 6 (100.0%) | 0 |
Previous treatment | |||
None | 12 (100.0%) | 6 (100.0%) | 0 |
ECOG score | |||
0 | 5 (41.7%) | 1 (16.7%) | 0.57 |
1 | 7 (58.3%) | 5 (83.3%) | 0.57 |
Disease free >12 months adjuvant to recurrence | |||
No | 12 (100.0%) | 6 (100.0%) | 0 |
Group 4: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.23\left(-0.61,0.15\right) \) | |||
n = 22 | n = 14 | ||
Age (years) | 63.7 (±6.2) | 62.3 (±5.1) | 0.24 |
Stage 4 | |||
No | 1 (4.5%) | 0 (0.0%) | 0.31 |
Yes | 21 (95.5%) | 14 (100.0%) | 0.31 |
Site | |||
Visceral | 17 (77.3%) | 12 (85.7%) | 0.22 |
Bone only | 5 (22.7%) | 2 (14.3%) | 0.22 |
Previous treatment | |||
None | 10 (45.5%) | 7 (50.0%) | 0.09 |
Chemo only | 5 (22.7%) | 5 (35.7%) | 0.29 |
Hormonal only | 4 (18.2%) | 1 (7.1%) | 0.34 |
Chemo + hormonal | 3 (13.6%) | 1 (7.1%) | 0.21 |
ECOG score | |||
0 | 22 (100.0%) | 14 (100.0%) | 0 |
Disease free >12 months adjuvant to recurrence | |||
No | 22 (100.0%) | 14 (100.0%) | 0 |
Group 5: not disease free >12 months adjuvant to recurrence \( \widehat{\Delta}=-0.64\left(-0.90,-0.39\right) \) | |||
n = 20 | n = 27 | ||
Age (years) | 67.3 (±4.5) | 66.5 (±5.1) | 0.15 |
Stage 4 | |||
No | 2 (10.0%) | 1 (3.7%) | 0.25 |
Yes | 18 (90.0%) | 26 (96.3%) | 0.25 |
Site | |||
Visceral | 17 (85.0%) | 22 (81.5%) | 0.09 |
Bone only | 3 (15.0%) | 5 (18.5%) | 0.09 |
Previous treatment | |||
None | 10 (50.0%) | 20 (74.1%) | 0.51 |
Chemo only | 4 (20.0%) | 1 (3.7%) | 0.52 |
Hormonal only | 4 (20.0%) | 5 (18.5%) | 0.04 |
Chemo + hormonal | 2 (10.0%) | 1 (3.7%) | 0.25 |
ECOG score | |||
1 | 20 (100.0%) | 27 (100.0%) | 0 |
Disease free >12 months adjuvant to recurrence | |||
No | 20 (100.0%) | 27 (100.0%) | 0 |